No Data
No Data
No Data
If Sukun Technology's “Big Road” is approved to update its prospectus, it can continue to impact the listing
According to an announcement from the China Securities Regulatory Commission on March 18, Sukun Technology, a leading medical AI company, has received official approval from the China Securities Regulatory Commission on its H-share listing application. The approval is valid for 12 months from the date of approval.
After 10 rounds of financing, Shikun Technology went to Hong Kong for an IPO: the net loss exceeded 300 million in two and a half years. When will it be profitable?
“Currently, the main difficulty in listing AI medical companies is that their profitability does not meet expectations.” According to Panhe Lin's analysis of Zhongxin Jingwei, there are two difficulties for AI medical companies to achieve profits: first, AI healthcare itself requires continuous algorithm optimization and requires a large amount of data to train AI. This itself is a long-term development; second, data-based AI medicine lacks continuous data acquisition and data cooperation capabilities. Recovering data from medical institutions has compliance issues, is too difficult to obtain, and data scale cannot be achieved.
Sukun Technology: The AI imaging company with the most certifications sprinted to the Hong Kong Stock Exchange and received support from Goldman Sachs, Sequoia, etc.
With the listing of this group of “real” AI companies, the market's investment logic and valuation in the AI industry are also being reshaped.
The medical AI “husband and wife shop” Shukun Technology went to Hong Kong for an IPO. Why is Maotai still losing money with gross margin comparable to that?
Will artificial intelligence impact the status of traditional doctors?
Jukun Science and Technology wants to build a "digital doctor" to help human doctors.
In 2021, Jikun Science and Technology launched liver MR artificial intelligence products, which were jointly developed by Professor Yang Zhenghan, director of the Department of Radiology of Beijing Friendship Hospital, and other R & D personnel, with the aim of solving complex liver disease diagnosis problems. For engineers and doctors, they are not proficient in each other's industry knowledge, and the research of artificial intelligence algorithms needs the cooperation of two fields of knowledge.
Jukun Technology to Hong Kong IPO: digital doctor products cover 80% of the top 100 hospitals? Attach importance to R & D and strengthen competitive barriers
Following the medical AI device company Keya Medical, AI Retinal Imaging Company Eagle pupil Technology and AI Medical Technology Company to submit IPO applications, on September 21, 2021, AI Digital Doctor platform Company Jukun Technology submitted a prospectus to the Hong Kong Stock Exchange to embrace the capital market.
No Data